REMEGEN (09995) surged nearly 9% again, rising 9.03% to HK$95.95 as of press time, with trading volume reaching HK$383 million.

On the news front, REMEGEN recently released its interim results, achieving operating revenue of 1.09 billion yuan in the first half, up 48% year-over-year; net loss attributable to shareholders was 450 million yuan, representing a loss reduction of 330 million yuan compared to the same period last year.

Everbright Securities noted that the company's revenue growth was primarily driven by continued increases in sales volumes of Telitacicept and Vedicitumab, leading to higher product sales revenue. Both core products entered the National Reimbursement Drug List in 2021.

CICC stated that the company's first-half performance met expectations. Currently, Telitacicept for gMG has received marketing approval, and the firm expects pSS and IgAN applications to be submitted in the second half of 2025. Vedicitumab for treating second-line HER2-positive breast cancer with liver metastases has been approved, while second-line HER2-low expressing breast cancer and first-line urothelial carcinoma indications have been submitted for approval. The firm expects that continuous expansion of core product indications will drive sustained acceleration in commercialization.